Please ensure Javascript is enabled for purposes of website accessibility

Here's What Pushed bluebird bio Stock Down 44.3% in 2018

By Cory Renauer - Updated Apr 17, 2019 at 5:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.

What happened

Depending on how you measure it, 2018 was a great year for bluebird bio (BLUE 2.80%). The company's cell-based therapies took big steps forward and produced impressive results. Disappointing early sales numbers for the types of treatments Bluebird's trying to hatch, though, caused investors to knock the stock 44.3% lower in 2018, according to data from S&P Global Market Intelligence.

So what 

Bluebird is developing a treatment for beta-thalassemia patients that appears capable of permanently reducing their need for regular blood transfusions after a single administration. It's also developing highly effective cancer therapies with a similar once-and-done approach. In 2018, competition on the way from some deep-pocketed competitors made investors nervous. Disappointing drug launches for complex one-time treatments in 2018 weighed heavily on the stock as well.

Downward-sloping chart drawn with chalk.

Image source: Getty Images.

Paying for treatments over the long term based on the outcomes they produce seems like a sensible solution. Unfortunately, insurers have been paying upfront for drugs whether they work or not since the beginning of time, and nothing changes quickly in the heavily regulated world of healthcare.

Near the end of 2017, the FDA approved Luxturna to prevent genetic blindness, and Spark Therapeutics (ONCE) launched the one-time injection with an $850,000 price tag. Spark offered insurers clawback rebates if patients lose their vision down the line, but it didn't help. Luxturna sales reached just $15.6 million during the first nine months of 2018.

Now what

A quick resolution to investor fears that Bluebird's treatments might not be commercially viable probably won't happen in the near term. Spark recently wrapped up its J.P. Morgan Healthcare Conference investor presentation without providing fourth-quarter sales details, which means they won't be good.  

Bluebird intends to offer insurers a chance to pay 20% upfront for their beta-thalassemia treatment, then continue paying unless patients require regular transfusions again. It's a sensible plan, but you shouldn't assume it has a chance until you see it work with your own two eyes.

Check out all our earnings call transcripts.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$4.40 (2.80%) $0.12
Spark Therapeutics Stock Quote
Spark Therapeutics

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.